Loading stock…

Laboratorios Farmaceuticos Rovi, S.A. (ROVI) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Laboratorios Farmaceuticos Rovi, S.A.

ROVIMarket cap $3.35BPrice $65.5

Country🇪🇸Spain

SectorHealthcare

IndustryPharmaceuticals

Manufactures injectable drugs and develops long-acting therapies, including a licensed technology behind Risperidone injections used for schizophrenia. This Spanish pharma also produces heparins and was a key vaccine-vial supplier during the COVID-19 rollout.

In Bastion Portfolios?

52W Return-6%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-0%3

Revenue Forecast

Rev CAGR (1y)+0%3

Rev CAGR (3y)+9%7

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1-15%2

EPS Growth Y+2+36%9

EPS Growth Y+3+27%8

Quality

Margins

EBIT Margin20%7

Net Income Margin24%8

Free Cash Flow Margin23%8

Debt

Net Debt/EBITDA-0.110

Efficiency

ROE29%9

ROA19%10

Earnings Stability44

GEAR+STRONG83

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)204

P/E Ratio (Forward 3y)145

P/BV4.24

EV Multiples

EV/EBITDA Fwd154

EV/EBIT Fwd184

Yield

Free Cash Flow Yield6.1%7

Dividend Yield1.3%4

Momentum

Short term

1 month return-2%7

3 month return+3%7

YTD return-8%4

Mid term

Price vs 52wHigh68%3

1 year return-1%4

Long term

3 year return+12%3

5 year return+14%4

Risk Shield

Price Risk

Beta0.95

Volatility29%7

Free Cash Flow

Free Cash Flow Margin23%8

Free Cash Flow Yield6.1%7

Quality

ROCE20%9

Earnings Stability44

Net Debt/EBITDA-0.110

02Growth

Is it actually growing, and how fast?

ROVILaboratorios Farmaceuticos Rovi, S.A.

Revenue FY25$873M

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y+0%3

Revenue, next 3Y, CAGR+9%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-15%2

EPS growth, FY27E+36%9

EPS growth, FY28E+27%8

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 9%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

Earnings are set to grow faster than sales (EPS about 27%/yr vs revenue 9%/yr), so margins should widen. One year dips: EPS falls 15% next year.

WEAKNESSES

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

ROVILaboratorios Farmaceuticos Rovi, S.A.

Total return Current452%

Price return Current404%

MOMENTUM RATING↗

AVERAGE35 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return+3%7

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high68%3

1-year return-1%4

3-year return+12%3

5-year return+14%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%) and over three months (+3%).

WATCH

Returns sit at the market level so far this year (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+12% over three years and +14% over five), behind 60% of the market.

It's down 0.8% over the past year, now 32% below its 52-week high. That is a touch behind the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Laboratorios Farmaceuticos Rovi, S.A.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ROVILaboratorios Farmaceuticos Rovi, S.A.

Revenue FY25$873M

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y+0%3

Revenue, next 3Y, CAGR+9%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-15%2

EPS growth, FY27E+36%9

EPS growth, FY28E+27%8

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 9%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

Earnings are set to grow faster than sales (EPS about 27%/yr vs revenue 9%/yr), so margins should widen. One year dips: EPS falls 15% next year.

WEAKNESSES

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

ROVILaboratorios Farmaceuticos Rovi, S.A.

Total return Current452%

Price return Current404%

MOMENTUM RATING↗

AVERAGE35 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return+3%7

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high68%3

1-year return-1%4

3-year return+12%3

5-year return+14%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%) and over three months (+3%).

WATCH

Returns sit at the market level so far this year (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+12% over three years and +14% over five), behind 60% of the market.

It's down 0.8% over the past year, now 32% below its 52-week high. That is a touch behind the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Laboratorios Farmaceuticos Rovi, S.A.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community